Skip to main content

Table 2 Eligibility for E1594 and SWOG9509

From: Eligibility of patients with advanced non-small cell lung cancer for phase III chemotherapy trials

  Prospective Data
N = 100 (%)
Retrospective Data
N = 85 (%)
Entire Cohort
N = 185 (%)
E1594:    
   Ineligible 61 (61%) 60 (70.5%) 121 (65%)
   Eligible 39 (39%) 22 (26%) 61 (33%)
   Not assessable 0 (0%) 3 (3.5%) 3 (2%)
SWOG 9509    
   Ineligible 66 (66%) 66 (78%) 132 (71%)
   Eligible 34 (34%) 16 (19%) 50 (27%)
   Not assessable 0 (0%) 3 (3.5%) 3 (2%)